Tokyo Tape
Sign in
← Chiome Bioscience

Half-year report · HY

4583.TEDINET S100YW7X
Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥274m2026-01-01 → 2026-06-30StandaloneNet sales
Revenue¥593m2025-01-01 → 2025-12-31StandaloneNet sales (5-year summary)
Revenue¥252m2025-01-01 → 2025-06-30StandaloneNet sales
Operating income−¥480m2026-01-01 → 2026-06-30StandaloneOperating income
Operating income−¥537m2025-01-01 → 2025-06-30StandaloneOperating income
Ordinary income−¥482m2026-01-01 → 2026-06-30StandaloneOrdinary income
Ordinary income−¥989m2025-01-01 → 2025-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥539m2025-01-01 → 2025-06-30StandaloneOrdinary income
Profit before tax−¥482m2026-01-01 → 2026-06-30StandaloneIncome before income taxes
Profit before tax−¥539m2025-01-01 → 2025-06-30StandaloneIncome before income taxes
Net income−¥483m2026-01-01 → 2026-06-30StandaloneProfit loss
Net income−¥983m2025-01-01 → 2025-12-31StandaloneNet income loss (5-year summary)
Net income−¥540m2025-01-01 → 2025-06-30StandaloneProfit loss
Total assets¥1.9bnat 2026-06-30StandaloneAssets
Total assets¥1.7bnat 2025-12-31StandaloneAssets
Total assets¥2.0bnat 2025-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥341mat 2026-06-30StandaloneLiabilities
Total liabilities¥605mat 2025-12-31StandaloneLiabilities
Net assets / equity¥1.6bnat 2026-06-30StandaloneNet assets
Net assets / equity¥1.1bnat 2025-12-31StandaloneNet assets
Net assets / equity¥1.5bnat 2025-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.4bnat 2026-06-30StandaloneCash and deposits
Cash and deposits¥1.2bnat 2025-12-31StandaloneCash and deposits
Cash & equivalents¥1.4bnat 2026-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2025-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31vStandaloneCash and cash equivalents
Operating cash flow−¥539m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥936m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥673m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow−¥4m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥55m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥710m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥133m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥85m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-6.622026-01-01 → 2026-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-14.472025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-7.972025-01-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio81.9%at 2026-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio64.1%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio76.9%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued78,940,200at 2026-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued68,453,800at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued68,053,800at 2025-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2026-01-01 → 2026-06-30−¥269m
Drug Discovery And Developmentreportable segmentsegment profit2026-01-01 → 2026-06-30−¥369m
Drug Discovery Supportreportable segmentrevenue2026-01-01 → 2026-06-30¥274m
Drug Discovery Supportreportable segmentrevenue external2026-01-01 → 2026-06-30¥274m
Drug Discovery Supportreportable segmentsegment profit2026-01-01 → 2026-06-30¥159m
Total Of Reportable Segments And Otherssegment totalrevenue2026-01-01 → 2026-06-30¥274m
Total Of Reportable Segments And Otherssegment totalrevenue external2026-01-01 → 2026-06-30¥274m
Total Of Reportable Segments And Otherssegment totalsegment profit2026-01-01 → 2026-06-30−¥210m
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥280m
Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-06-30−¥396m
Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-06-30¥252m
Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-06-30¥252m
Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-06-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-06-30−¥257m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 430
ItemContextValueUnit
Deposits receivedInterimInstant_NonConsolidatedMember6489000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember374885000JPY
Current liabilitiesInterimInstant_NonConsolidatedMember285491000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember55554000JPY
Asset retirement obligations nclInterimInstant_NonConsolidatedMember55773000JPY
Bonds payablePrior1YearInstant_NonConsolidatedMember175000000JPY
Bonds payableInterimInstant_NonConsolidatedMember－JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember230554000JPY
Noncurrent liabilitiesInterimInstant_NonConsolidatedMember55773000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember605440000JPY
LiabilitiesInterimInstant_NonConsolidatedMember341264000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember1085523000JPY
Capital stockInterimInstant_NonConsolidatedMember1554710000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember2025797000JPY
Capital surplusInterimInstant_NonConsolidatedMember2494984000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-2003555000JPY
Retained earningsInterimInstant_NonConsolidatedMember-2486798000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockInterimInstant_NonConsolidatedMember-310000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1107473000JPY
Shareholders equityInterimInstant_NonConsolidatedMember1562585000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember14591000JPY
Subscription rights to sharesInterimInstant_NonConsolidatedMember3275000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1122064000JPY
Net assetsInterimInstant_NonConsolidatedMember1565861000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember1727504000JPY
Liabilities and net assetsInterimInstant_NonConsolidatedMember1907125000JPY
Net salesPrior1InterimDuration_NonConsolidatedMember251796000JPY
Net salesInterimDuration_NonConsolidatedMember273659000JPY
Cost of salesPrior1InterimDuration_NonConsolidatedMember112930000JPY
Cost of salesInterimDuration_NonConsolidatedMember115137000JPY
Gross profitPrior1InterimDuration_NonConsolidatedMember138866000JPY
Gross profitInterimDuration_NonConsolidatedMember158522000JPY
Research and development expenses sgaPrior1InterimDuration_NonConsolidatedMember395868000JPY
Research and development expenses sgaInterimDuration_NonConsolidatedMember368984000JPY
Other sgaPrior1InterimDuration_NonConsolidatedMember279819000JPY
Other sgaInterimDuration_NonConsolidatedMember269254000JPY
Selling general and administrative expensesPrior1InterimDuration_NonConsolidatedMember675688000JPY
Selling general and administrative expensesInterimDuration_NonConsolidatedMember638239000JPY
Operating incomePrior1InterimDuration_NonConsolidatedMember-536822000JPY
Operating incomeInterimDuration_NonConsolidatedMember-479717000JPY
Interest income noiPrior1InterimDuration_NonConsolidatedMember910000JPY
Interest income noiInterimDuration_NonConsolidatedMember1154000JPY
Foreign exchange gains noiPrior1InterimDuration_NonConsolidatedMember220000JPY
Foreign exchange gains noiInterimDuration_NonConsolidatedMember286000JPY
Other noiPrior1InterimDuration_NonConsolidatedMember132000JPY
Other noiInterimDuration_NonConsolidatedMember155000JPY
Non operating incomePrior1InterimDuration_NonConsolidatedMember1263000JPY
Non operating incomeInterimDuration_NonConsolidatedMember1596000JPY
Interest expenses noePrior1InterimDuration_NonConsolidatedMember1940000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2025-12-31pass
balance sheet identitynon_consolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · net assetsnon_consolidated 2026-06-30pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flownon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass
statement vs summary · total assetsnon_consolidated 2026-06-30pass